3,4-dihydroxyphenylacetic acid has been researched along with Disease Models, Animal in 301 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The fact that amphetamine, a noradrenaline releaser, prevents motion sickness leads the hypothesis of Wood and Graybiel that the noradrenergic neuron system in the brain stem acts against the development of motion sickness." | 7.68 | Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. ( Matsunaga, T; Morita, M; Takeda, N; Wada, H; Yamatodani, A, 1990) |
| "Depression is one of the most common associated diseases, which aggravates psoriatic skin lesions and affects the life quality of patients." | 5.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "Tamoxifen (TMX) is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer." | 5.43 | Memory enhancement by Tamoxifen on amyloidosis mouse model. ( Banerjee, S; Basu, M; Mishra, N; Pandey, D, 2016) |
| " The aim of our study was to investigate abnormalities in the mesolimbic pathway associated with morphine dependence and withdrawal." | 3.81 | Dysregulation of dopaminergic regulatory mechanisms in the mesolimbic pathway induced by morphine and morphine withdrawal. ( García-Pérez, D; Laorden, ML; López-Bellido, R; Milanés, MV; Núñez, C; Rodríguez, RE, 2015) |
| " Dopamine levels may not directly modulate the refractive state of the mouse eye, but tonic levels of dopamine during development may determine susceptibility to myopia." | 3.80 | Visually-driven ocular growth in mice requires functional rod photoreceptors. ( Abey, J; Aseem, F; Iuvone, PM; Jabbar, SB; Pardue, MT; Park, Hn; Schmid, G; Sidhu, CS; Tan, CC, 2014) |
| "The experimental model of seizures which depends upon methionine sulfoximine (MSO) simulates the most striking form of human epilepsy." | 3.79 | Monoamines and glycogen levels in cerebral cortices of fast and slow methionine sulfoximine-inbred mice. ( Boissonnet, A; Cloix, JF; Hévor, T; Landemarre, L, 2013) |
| " N-Methyl(R)salsolinol induced DNA damage to human neuroblastoma SH-SY5Y cells, which could be prevented by anti-oxidants and cycloheximide." | 3.70 | Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines. ( Dostert, P; Kasamatsu, T; Maruyama, W; Naoi, M, 1998) |
| "We have investigated the effect of tyrosine administration on the cognitive and neurochemical alterations caused by diet restriction (DR) in mice, as a possible model for some of the behavioral symptoms of patients with anorexia nervosa." | 3.69 | Behavioral and neurochemical alterations caused by diet restriction--the effect of tyrosine administration in mice. ( Avraham, Y; Berry, EM; Bonne, O, 1996) |
| "Intracerebral microdialysis was applied to monitor the neocortical extracellular levels of the aromatic amino acids phenylalanine, tyrosine, and tryptophan, the neurotransmitters dopamine (DA), noradrenaline (NA), and serotonin (5-HT), and the metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindole-3-acetic acid (5-HIAA) in rats with various forms of experimental hepatic encephalopathy (HE)." | 3.69 | Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt. ( Bengtsson, F; Bergqvist, PB; Bosman, DK; Chamuleau, RA; Hjorth, S; Maas, MA; Vogels, BA, 1995) |
| "The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques." | 3.68 | Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990) |
| "The fact that amphetamine, a noradrenaline releaser, prevents motion sickness leads the hypothesis of Wood and Graybiel that the noradrenergic neuron system in the brain stem acts against the development of motion sickness." | 3.68 | Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness. ( Matsunaga, T; Morita, M; Takeda, N; Wada, H; Yamatodani, A, 1990) |
| "Myopia, or nearsightedness, is the most common form of refractive abnormality and is characterized by excessive ocular elongation in relation to ocular power." | 1.72 | Melanopsin modulates refractive development and myopia. ( Chakraborty, R; Hattar, S; Iuvone, PM; Landis, EG; Mazade, R; Pardue, MT; Stone, RA; Strickland, R; Yang, V, 2022) |
| "Schizophrenia is probably ascribed to perinatal neurodevelopmental deficits, and its onset might be affected by environmental factors." | 1.62 | Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors. ( Hata, T; Hiraga, T; Koizumi, H; Mouri, A; Nabeshima, T; Oharomari, LK; Okamoto, M; Shima, T; Soya, H; Yook, JS, 2021) |
| " Its bioavailability is, however, low and, therefore, its metabolites could rather be responsible for this effect." | 1.56 | A Mixture of Phenolic Metabolites of Quercetin Can Decrease Elevated Blood Pressure of Spontaneously Hypertensive Rats Even in Low Doses. ( Mladěnka, P; Najmanová, I; Pourová, J, 2020) |
| "Depression is one of the most common associated diseases, which aggravates psoriatic skin lesions and affects the life quality of patients." | 1.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "Depression is one of the main non-motor symptoms of PD." | 1.51 | Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test. ( Haider, S; Madiha, S, 2019) |
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| "Monocular myopia was induced by unilateral form-deprivation (FD)." | 1.48 | Dopamine Receptor Subtypes Mediate Opposing Effects on Form Deprivation Myopia in Pigmented Guinea Pigs. ( Fan, M; Pan, M; Qu, J; Reinach, PS; Wang, F; Yang, J; Ying, H; Zhang, L; Zhang, S; Zhou, X, 2018) |
| "Tamoxifen (TMX) is a selective estrogen receptor modulator (SERM) used in the treatment of breast cancer." | 1.43 | Memory enhancement by Tamoxifen on amyloidosis mouse model. ( Banerjee, S; Basu, M; Mishra, N; Pandey, D, 2016) |
| " Chronic administration of curcumin significantly reversed levels of 3, 4-dihydroxyphenylacetic acid, noradrenaline, serotonin and 5-hydroxyindoleacetic acid in the hippocampus region of male albino rats." | 1.43 | Analysis of anti-depressant potential of curcumin against depression induced male albino wistar rats. ( Chang, XR; Li, J; Wang, L; Wu, DS, 2016) |
| "We have previously shown that food allergy impaired social behaviour in mice." | 1.42 | Dietary long chain n-3 polyunsaturated fatty acids prevent impaired social behaviour and normalize brain dopamine levels in food allergic mice. ( Broersen, LM; de Theije, CG; Garssen, J; Korte, SM; Korte-Bouws, GA; Kraneveld, AD; Lopes da Silva, S; Milosevic, V; Olivier, B; van den Elsen, LW; Willemsen, LE, 2015) |
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| " The enhanced stability and bioavailability of PEGylated rhFGF-2 make this molecule a great therapeutic candidate for neurodegenerative diseases such as PD and mood disorders." | 1.42 | PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease. ( Chen, G; Feng, J; Feng, W; Huang, Z; Niu, J; Shi, L; Wang, Y; Ye, C; Zhu, G, 2015) |
| " Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i." | 1.40 | Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates. ( Davydova, TV; Fomina, VG; Gruden, MA; Kudrin, VS; Morozova-Roche, LA; Narkevich, VB; Sewell, RD; Wang, C, 2014) |
| "Post-Traumatic Stress Disorder (PTSD) can develop in response to a traumatic event involving a threat to life." | 1.40 | Predator exposure/psychosocial stress animal model of post-traumatic stress disorder modulates neurotransmitters in the rat hippocampus and prefrontal cortex. ( Ebenezer, PJ; Francis, J; McLaughlin, LD; Wilson, CB, 2014) |
| "A goldfish (Carassius auratus) model of Parkinson's disease (PD) was constructed by a single dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to previously reported methods." | 1.40 | (1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Kong, L; Li, M; Liu, Q; Lu, Z; Wang, J; Wei, D; Yang, M, 2014) |
| "Menkes disease is a lethal neurodegenerative disorder of infancy caused by mutations in a copper-transporting adenosine triphosphatase gene, ATP7A." | 1.39 | L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model. ( Brinster, LR; Donsante, A; Goldstein, DS; Kaler, SG; Sullivan, P, 2013) |
| "ADHs are of interest in Parkinson's disease (PD) since these compounds can be harmful to dopamine (DA) neurons." | 1.38 | Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease. ( Anvret, A; Belin, AC; Duester, G; Felder, MR; Galter, D; Gellhaar, S; Lindqvist, E; Lundströmer, K; Pernold, K; Ran, C; Westerlund, M, 2012) |
| "Melatonin has ubiquitous actions, both as a direct free-radical scavenger and as an indirect anti-oxidant." | 1.38 | Neuroprotective effects of melatonin on the nigrostriatal dopamine system in the zitter rat. ( Ehara, A; Hashimoto, K; Hirata, K; Sakakibara, S; Ueda, S; Yoshimoto, K, 2012) |
| "In humans, depression is associated with altered rapid eye movement (REM) sleep." | 1.38 | Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats. ( Huang, ZL; Li, R; Qu, WM; Tu, ZC; Urade, Y; Wang, YQ; Xu, XY, 2012) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| " In conclusion, our data suggest that low dosage of MA worsens the suppression of locomotor responses and striatal dopamine turnover after mTBI." | 1.37 | Methamphetamine potentiates behavioral and electrochemical responses after mild traumatic brain injury in mice. ( Chiang, YH; Harvey, BK; Pick, CG; Shen, H; Wang, Y, 2011) |
| "The effects of GB-115 dipeptide, a retroanalog of endogenous CCK-4, on the behavioral indices in "elevated plus maze" (EPM) test and on the content of biogenic amines in the brain structures after discontinuation of a chronic administration of benzodiazepine (BZ) derivatives phenazepam (2." | 1.37 | [Effect of GB-115 dipeptide on anxiety in rats with model benzodiazepine withdrawal syndrome]. ( Gudasheva, TA; Kadnikov, IA; Kolik, LG; Seredenin, SB; Zhukov, VN, 2011) |
| " Chronic administration of clozapine (5 mg/kg s." | 1.36 | Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. ( Cilia, J; Dawson, LA; Gartlon, JE; Jones, DN; Moore, SH; Shilliam, C, 2010) |
| "Zonisamide treatment alone did not produce any lasting effects on ex vivo MAO-B activity, indicating that it is a reversible inhibitor of the enzyme." | 1.36 | The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. ( Buckley, B; Sonsalla, PK; Winnik, B; Wong, LY, 2010) |
| "Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals." | 1.36 | Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010) |
| "Memantine was administered two weeks post infection, at peak viremia, in order to prevent early NMDA receptor activation due to immune mediators." | 1.35 | Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. ( Kneitz, S; Koutsilieri, E; Meisner, F; Neuen-Jacob, E; Riederer, P; Scheller, C; Sopper, S; ter Meulen, V, 2008) |
| "Rosiglitazone is a commonly prescribed insulin-sensitizing drug with a selective agonistic activity on the peroxisome proliferator-activated receptor-gamma (PPAR-gamma)." | 1.35 | PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. ( Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N, 2009) |
| " Acute or chronic administration of methamphetamine elevates the levels of the extracellular monoamine neurotransmitters, such as dopamine." | 1.35 | Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring. ( Bubenikova-Valesova, V; Hruba, L; Janovsky, M; Kacer, P; Rambousek, L; Schutova, B; Slamberova, R; Syslova, K, 2009) |
| " Estrogen altered the toxic effects of the second invasion of MA as indicated by a significant decrease in striatal dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations." | 1.33 | Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. ( Dluzen, DE; Liu, B, 2006) |
| "The MFB lesion model mimics end-stage Parkinson's disease." | 1.33 | Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. ( Ebinger, G; Michotte, Y; Sarre, S; Yuan, H, 2005) |
| "The aetiology of idiopathic Parkinson's disease (PD) is poorly defined but environmental aggression may be relevant." | 1.33 | Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. ( Cavada, C; Close, RM; Cuadrado, A; de Sagarra, MR; Fernández-Ruiz, J; Jackson-Lewis, V; Montero, C; Rojo, AI; Salazar, M; Sánchez-González, MA, 2006) |
| " Long recovery periods after MPP(+) exposure are required to distinguish between reversible or irreversible toxic and/or trophic effects." | 1.33 | Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF. ( Gramsbergen, JB; Jakobsen, B; Møller Dall, A; Rosenblad, C; Zimmer, J, 2005) |
| " Because of their ability to combat oxidative stress, diet derived phenolic compounds continue to be considered as potential agents for long-term use in PD." | 1.33 | Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. ( Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V, 2005) |
| " Therefore, the aim of the present study was to examine whether the long-term administration of a commonly used herbicide, paraquat, which has already been found to induce a slowly progressing degeneration of the nigrostriatal neurons, influences mesocortical dopaminergic neurons in rats." | 1.33 | Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. ( Biedka, I; Bortel, A; Dabrowska, J; Kuter, K; Nowak, P; Ossowska, K; Rommelspacher, H; Schulze, G; Smiałowska, M; Wardas, J; Wierońska, J; Zieba, B, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Tolcapone treatment enhanced CSF DOPAC concentrations in unlesioned animals (by approximately four times) as well as monkeys rendered parkinsonian after severe nigrostriatal dopaminergic injury caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)." | 1.32 | Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. ( Di Monte, DA; Langston, JW; Thiffault, C, 2003) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| " Although increasing the dosage of d-METH (20 to 80 mg/kg) did increase the GFAP response (100% over control), it was still well below that usually exhibited at the usual neurotoxic dosage (300-400% over control) in fully mature mice." | 1.31 | Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. ( Ali, SF; Miller, DB; O'Callaghan, JP, 2000) |
| " Previous studies have shown that chronic administration of antidepressants can reverse this behavioural deficit." | 1.30 | Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. ( Kelly, JP; Leonard, BE; Redmond, AM, 1997) |
| "That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons." | 1.30 | Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997) |
| "The hyperphagia was further enhanced when they were put in a space-restricted cage where their mobility was restricted." | 1.30 | Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction--a rat model of binge eating. ( Fujisaki, Y; Inoue, K; Iwasaki, S; Kiriike, N; Kurioka, M; Okuno, M; Yamagami, S, 1998) |
| "Investigations of gene therapy for Parkinson's disease have focused primarily on strategies that replace tyrosine hydroxylase." | 1.30 | Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. ( Bencsics, C; Kang, UJ; Wachtel, SR, 1997) |
| "The behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset." | 1.29 | Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. ( Albanese, A; Colosimo, C; Granata, R; Gregori, B; Piccardi, MP; Tonali, P, 1993) |
| " These results indicate that chronic administration of either bromocriptine or L-Dopa will reverse the DA receptor denervation supersensitivity in striatum seen following 6-OHDA lesion." | 1.27 | Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. ( Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (4.98) | 18.7374 |
| 1990's | 39 (12.96) | 18.2507 |
| 2000's | 130 (43.19) | 29.6817 |
| 2010's | 106 (35.22) | 24.3611 |
| 2020's | 11 (3.65) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Chakraborty, R | 4 |
| Landis, EG | 3 |
| Mazade, R | 1 |
| Yang, V | 2 |
| Strickland, R | 1 |
| Hattar, S | 1 |
| Stone, RA | 1 |
| Iuvone, PM | 9 |
| Pardue, MT | 6 |
| Tian, P | 1 |
| Zhang, W | 1 |
| Li, KY | 1 |
| Li, HW | 1 |
| Ma, K | 1 |
| Han, DE | 1 |
| Xu, X | 1 |
| Shi, J | 1 |
| Zhang, C | 1 |
| Shi, L | 2 |
| Bai, Y | 1 |
| Shi, W | 1 |
| Wang, Y | 6 |
| Najmanová, I | 2 |
| Pourová, J | 2 |
| Mladěnka, P | 2 |
| Thakur, V | 1 |
| Jamwal, S | 1 |
| Kumar, M | 1 |
| Rahi, V | 1 |
| Kumar, P | 1 |
| Kao, CY | 1 |
| Xu, M | 1 |
| Wang, L | 2 |
| Lin, SC | 1 |
| Lee, HJ | 1 |
| Duraine, L | 1 |
| Bellen, HJ | 2 |
| Goldstein, DS | 5 |
| Tsai, SY | 1 |
| Tsai, MJ | 1 |
| Valent, D | 1 |
| Arroyo, L | 1 |
| Fàbrega, E | 1 |
| Font-I-Furnols, M | 1 |
| Rodríguez-Palmero, M | 1 |
| Moreno-Muñoz, JA | 1 |
| Tibau, J | 1 |
| Bassols, A | 1 |
| Chen, YB | 1 |
| Wang, YQ | 2 |
| Wu, JR | 1 |
| Cui, YL | 1 |
| Koizumi, H | 1 |
| Hiraga, T | 1 |
| Oharomari, LK | 1 |
| Hata, T | 1 |
| Shima, T | 1 |
| Yook, JS | 1 |
| Okamoto, M | 1 |
| Mouri, A | 1 |
| Nabeshima, T | 1 |
| Soya, H | 1 |
| Guo, J | 2 |
| Liu, Y | 1 |
| Guo, X | 2 |
| Meng, Y | 1 |
| Qi, C | 1 |
| Zhao, J | 1 |
| Di, T | 1 |
| Zhang, L | 3 |
| Li, P | 2 |
| Antkiewicz-Michaluk, L | 1 |
| Romańska, I | 1 |
| Wąsik, A | 1 |
| Michaluk, J | 1 |
| Madiha, S | 2 |
| Tabassum, S | 1 |
| Batool, Z | 1 |
| Liaquat, L | 1 |
| Sadir, S | 1 |
| Shahzad, S | 1 |
| Perveen, T | 1 |
| Haider, S | 2 |
| Mamalyga, ML | 1 |
| Mamalyga, LM | 1 |
| Miner, NB | 1 |
| Elmore, JS | 1 |
| Baumann, MH | 1 |
| Phillips, TJ | 1 |
| Janowsky, A | 1 |
| Luo, X | 1 |
| Li, B | 1 |
| Li, T | 1 |
| Di, Y | 1 |
| Zheng, C | 1 |
| Ji, S | 1 |
| Ma, Y | 1 |
| Zhu, J | 1 |
| Chen, X | 2 |
| Zhou, X | 2 |
| Landrock, KK | 1 |
| Sullivan, P | 3 |
| Martini-Stoica, H | 1 |
| Graham, BH | 1 |
| Yamamoto, S | 2 |
| Gibbs, RA | 1 |
| Chen, R | 1 |
| D'Amelio, M | 1 |
| Stoica, G | 1 |
| Ren, M | 1 |
| Guo, Y | 1 |
| Wei, X | 1 |
| Yan, S | 1 |
| Qin, Y | 1 |
| Zhang, X | 1 |
| Jiang, F | 1 |
| Lou, H | 1 |
| Moreno-Galarza, N | 1 |
| Mendieta, L | 1 |
| Palafox-Sánchez, V | 1 |
| Herrando-Grabulosa, M | 1 |
| Gil, C | 1 |
| Limón, DI | 1 |
| Aguilera, J | 1 |
| Itzhacki, J | 1 |
| Clesse, D | 1 |
| Goumon, Y | 1 |
| Van Someren, EJ | 1 |
| Mendoza, J | 1 |
| Abdel-Hafiz, L | 1 |
| Müller-Schiffmann, A | 1 |
| Korth, C | 1 |
| Fazari, B | 1 |
| Chao, OY | 3 |
| Nikolaus, S | 2 |
| Schäble, S | 1 |
| Herring, A | 1 |
| Keyvani, K | 1 |
| Lamounier-Zepter, V | 1 |
| Huston, JP | 5 |
| de Souza Silva, MA | 1 |
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 4 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Vopršalová, M | 1 |
| Migkos, T | 1 |
| Pilařová, V | 1 |
| Applová, L | 1 |
| Nováková, L | 1 |
| Zhang, S | 1 |
| Yang, J | 3 |
| Reinach, PS | 1 |
| Wang, F | 2 |
| Fan, M | 1 |
| Ying, H | 1 |
| Pan, M | 1 |
| Qu, J | 1 |
| Park, HN | 3 |
| Dhakal, S | 1 |
| Motz, CT | 1 |
| Bergen, MA | 2 |
| Puginier, E | 1 |
| Bharatiya, R | 1 |
| Chagraoui, A | 1 |
| Manem, J | 1 |
| Cho, YH | 1 |
| Garret, M | 1 |
| De Deurwaerdère, P | 1 |
| Lv, DJ | 1 |
| Li, LX | 1 |
| Chen, J | 2 |
| Wei, SZ | 1 |
| Hu, H | 1 |
| Xie, AM | 1 |
| Liu, CF | 1 |
| Delli Pizzi, S | 1 |
| Rossi, C | 1 |
| Di Matteo, V | 2 |
| Esposito, E | 2 |
| Guarnieri, S | 1 |
| Mariggiò, MA | 1 |
| Franciotti, R | 1 |
| Caulo, M | 1 |
| Thomas, A | 1 |
| Onofrj, M | 1 |
| Tartaro, A | 1 |
| Bonanni, L | 1 |
| Martin, HL | 2 |
| Mounsey, RB | 1 |
| Sathe, K | 1 |
| Mustafa, S | 2 |
| Nelson, MC | 1 |
| Evans, RM | 1 |
| Teismann, P | 5 |
| Jones, BC | 2 |
| Miller, DB | 3 |
| O'Callaghan, JP | 3 |
| Lu, L | 2 |
| Unger, EL | 1 |
| Alam, G | 2 |
| Williams, RW | 3 |
| Krasnova, IN | 2 |
| Chiflikyan, M | 1 |
| Justinova, Z | 1 |
| McCoy, MT | 1 |
| Ladenheim, B | 1 |
| Jayanthi, S | 1 |
| Quintero, C | 1 |
| Brannock, C | 1 |
| Barnes, C | 1 |
| Adair, JE | 1 |
| Lehrmann, E | 1 |
| Kobeissy, FH | 1 |
| Gold, MS | 1 |
| Becker, KG | 1 |
| Goldberg, SR | 1 |
| Cadet, JL | 2 |
| Petri, D | 1 |
| Pum, M | 1 |
| Vesper, J | 1 |
| Schnitzler, A | 1 |
| Rodríguez-Arias, M | 1 |
| Valverde, O | 1 |
| Daza-Losada, M | 1 |
| Blanco-Gandía, MC | 1 |
| Aguilar, MA | 1 |
| Miñarro, J | 1 |
| Rekha, KR | 1 |
| Selvakumar, GP | 1 |
| Santha, K | 1 |
| Inmozhi Sivakamasundari, R | 1 |
| Zhang, N | 1 |
| Favazza, TL | 1 |
| Baglieri, AM | 1 |
| Benador, IY | 1 |
| Noonan, ER | 1 |
| Fulton, AB | 1 |
| Hansen, RM | 1 |
| Akula, JD | 1 |
| Yamamoto, T | 1 |
| Uchiyama, T | 1 |
| Sakakibara, R | 1 |
| Taniguchi, J | 1 |
| Kuwabara, S | 1 |
| Ngwa, HA | 1 |
| Kanthasamy, A | 1 |
| Jin, H | 1 |
| Anantharam, V | 1 |
| Kanthasamy, AG | 1 |
| Gruden, MA | 1 |
| Davydova, TV | 1 |
| Narkevich, VB | 1 |
| Fomina, VG | 1 |
| Wang, C | 1 |
| Kudrin, VS | 1 |
| Morozova-Roche, LA | 1 |
| Sewell, RD | 1 |
| Wilson, CB | 1 |
| Ebenezer, PJ | 1 |
| McLaughlin, LD | 1 |
| Francis, J | 1 |
| Miao, SH | 1 |
| Sun, HB | 1 |
| Ye, Y | 1 |
| Yang, JJ | 1 |
| Shi, YW | 1 |
| Lu, M | 1 |
| Hu, G | 2 |
| Zhou, JW | 1 |
| Jiang, H | 1 |
| Li, F | 1 |
| Liu, S | 1 |
| Sun, H | 1 |
| Cui, Y | 1 |
| Wu, Y | 1 |
| García-Pérez, D | 1 |
| López-Bellido, R | 1 |
| Rodríguez, RE | 1 |
| Laorden, ML | 1 |
| Núñez, C | 1 |
| Milanés, MV | 1 |
| Rose, KM | 1 |
| Parmar, MS | 1 |
| Cavanaugh, JE | 1 |
| Feng, G | 1 |
| Zhang, Z | 2 |
| Bao, Q | 1 |
| Zhou, L | 1 |
| Jiang, J | 1 |
| Li, S | 1 |
| Zhu, G | 1 |
| Chen, G | 2 |
| Feng, J | 1 |
| Ye, C | 1 |
| Feng, W | 1 |
| Niu, J | 1 |
| Huang, Z | 1 |
| Morin, N | 1 |
| Morissette, M | 2 |
| Grégoire, L | 1 |
| Di Paolo, T | 1 |
| Jabbar, SB | 1 |
| Tan, CC | 1 |
| Sidhu, CS | 2 |
| Abey, J | 1 |
| Aseem, F | 1 |
| Schmid, G | 1 |
| Han, B | 1 |
| Jin, HJ | 1 |
| Song, MY | 1 |
| Wang, T | 1 |
| Zhao, H | 1 |
| Lu, Z | 1 |
| Wang, J | 1 |
| Li, M | 1 |
| Liu, Q | 1 |
| Wei, D | 2 |
| Yang, M | 1 |
| Kong, L | 1 |
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 2 |
| Saal, KA | 1 |
| Koch, JC | 1 |
| Tatenhorst, L | 1 |
| Szegő, EM | 1 |
| Ribas, VT | 1 |
| Michel, U | 1 |
| Tönges, L | 1 |
| Lingor, P | 2 |
| Renoir, T | 1 |
| Argyropoulos, A | 1 |
| Chevarin, C | 1 |
| Lanfumey, L | 1 |
| Hannan, AJ | 1 |
| de Theije, CG | 1 |
| van den Elsen, LW | 1 |
| Willemsen, LE | 1 |
| Milosevic, V | 1 |
| Korte-Bouws, GA | 2 |
| Lopes da Silva, S | 1 |
| Broersen, LM | 1 |
| Korte, SM | 3 |
| Olivier, B | 1 |
| Garssen, J | 1 |
| Kraneveld, AD | 1 |
| Benskey, MJ | 1 |
| Manfredsson, FP | 1 |
| Lookingland, KJ | 1 |
| Goudreau, JL | 1 |
| Lei, P | 1 |
| Ayton, S | 1 |
| Appukuttan, AT | 1 |
| Volitakis, I | 1 |
| Adlard, PA | 1 |
| Finkelstein, DI | 1 |
| Bush, AI | 1 |
| Willard, AM | 1 |
| Bouchard, RS | 1 |
| Gittis, AH | 1 |
| Sharma, N | 1 |
| Nehru, B | 1 |
| Chen, S | 1 |
| Zhang, XJ | 1 |
| Xie, WJ | 1 |
| Qiu, HY | 1 |
| Liu, H | 1 |
| Le, WD | 1 |
| Zhou, JJ | 1 |
| Zhai, SY | 1 |
| Zhang, HN | 1 |
| Wang, YH | 1 |
| Pu, XP | 1 |
| Haque, R | 2 |
| Fernandes, A | 2 |
| Lambert, SR | 1 |
| Pandey, D | 1 |
| Banerjee, S | 1 |
| Basu, M | 1 |
| Mishra, N | 1 |
| Santoro, M | 1 |
| Riedel, G | 1 |
| Forrester, JV | 1 |
| Golko-Perez, S | 1 |
| Mandel, S | 1 |
| Amit, T | 1 |
| Kupershmidt, L | 1 |
| Youdim, MB | 3 |
| Weinreb, O | 1 |
| Tran, S | 1 |
| Nowicki, M | 1 |
| Fulcher, N | 1 |
| Chatterjee, D | 1 |
| Gerlai, R | 1 |
| Hirth, N | 1 |
| Meinhardt, MW | 1 |
| Noori, HR | 1 |
| Salgado, H | 1 |
| Torres-Ramirez, O | 1 |
| Uhrig, S | 1 |
| Broccoli, L | 1 |
| Vengeliene, V | 1 |
| Roßmanith, M | 1 |
| Perreau-Lenz, S | 1 |
| Köhr, G | 1 |
| Sommer, WH | 1 |
| Spanagel, R | 1 |
| Hansson, AC | 1 |
| Chang, XR | 1 |
| Li, J | 2 |
| Wu, DS | 1 |
| Melief, EJ | 1 |
| Gibbs, JT | 1 |
| Li, X | 1 |
| Morgan, RG | 1 |
| Keene, CD | 1 |
| Montine, TJ | 1 |
| Palmiter, RD | 1 |
| Darvas, M | 1 |
| Klein, C | 1 |
| Rasińska, J | 1 |
| Empl, L | 1 |
| Sparenberg, M | 1 |
| Poshtiban, A | 1 |
| Hain, EG | 1 |
| Iggena, D | 1 |
| Rivalan, M | 1 |
| Winter, Y | 1 |
| Steiner, B | 1 |
| Janphet, S | 1 |
| Nudmamud-Thanoi, S | 1 |
| Thanoi, S | 1 |
| Didriksen, M | 1 |
| Fejgin, K | 1 |
| Nilsson, SR | 1 |
| Birknow, MR | 1 |
| Grayton, HM | 1 |
| Larsen, PH | 1 |
| Lauridsen, JB | 1 |
| Nielsen, V | 1 |
| Celada, P | 1 |
| Santana, N | 1 |
| Kallunki, P | 1 |
| Christensen, KV | 1 |
| Werge, TM | 1 |
| Stensbøl, TB | 1 |
| Egebjerg, J | 1 |
| Gastambide, F | 1 |
| Artigas, F | 1 |
| Bastlund, JF | 1 |
| Nielsen, J | 1 |
| Sidhu, C | 1 |
| He, L | 1 |
| Markand, S | 1 |
| Baskin, NL | 1 |
| Landis, E | 1 |
| Wetzstein, SA | 1 |
| Donaldson, KJ | 1 |
| Priyadarshani, P | 1 |
| Alderson, SE | 1 |
| Boatright, JH | 1 |
| Nickerson, JM | 1 |
| Iwata, Y | 1 |
| Suzuki, K | 1 |
| Wakuda, T | 1 |
| Seki, N | 1 |
| Thanseem, I | 1 |
| Matsuzaki, H | 1 |
| Mamiya, T | 1 |
| Ueki, T | 1 |
| Mikawa, S | 1 |
| Sasaki, T | 1 |
| Suda, S | 1 |
| Tsuchiya, KJ | 1 |
| Sugihara, G | 1 |
| Nakamura, K | 1 |
| Sato, K | 1 |
| Takei, N | 1 |
| Hashimoto, K | 2 |
| Mori, N | 1 |
| Anderson, DW | 1 |
| Bradbury, KA | 1 |
| Schneider, JS | 1 |
| Minematsu, M | 1 |
| Nakajima, K | 1 |
| Boulet, S | 1 |
| Mounayar, S | 1 |
| Poupard, A | 1 |
| Bertrand, A | 1 |
| Jan, C | 1 |
| Pessiglione, M | 1 |
| Hirsch, EC | 3 |
| Feuerstein, C | 1 |
| François, C | 1 |
| Féger, J | 1 |
| Savasta, M | 1 |
| Tremblay, L | 1 |
| Xu, L | 1 |
| Liu, LX | 2 |
| Chen, WF | 2 |
| Verhagen, LA | 1 |
| Luijendijk, MC | 1 |
| Adan, RA | 1 |
| Cilia, J | 1 |
| Gartlon, JE | 1 |
| Shilliam, C | 1 |
| Dawson, LA | 1 |
| Moore, SH | 1 |
| Jones, DN | 1 |
| Schintu, N | 1 |
| Frau, L | 1 |
| Ibba, M | 1 |
| Caboni, P | 1 |
| Garau, A | 1 |
| Carboni, E | 1 |
| Carta, AR | 1 |
| Pais-Vieira, M | 1 |
| Mendes-Pinto, MM | 1 |
| Lima, D | 1 |
| Galhardo, V | 1 |
| Kraft, JC | 1 |
| Osterhaus, GL | 1 |
| Ortiz, AN | 1 |
| Garris, PA | 2 |
| Johnson, MA | 1 |
| Samad, N | 1 |
| Haleem, DJ | 1 |
| Bubenikova-Valesova, V | 1 |
| Kacer, P | 1 |
| Syslova, K | 1 |
| Rambousek, L | 1 |
| Janovsky, M | 1 |
| Schutova, B | 1 |
| Hruba, L | 1 |
| Slamberova, R | 1 |
| Gal, S | 1 |
| Zheng, H | 1 |
| Fridkin, M | 1 |
| RajaSankar, S | 1 |
| Manivasagam, T | 1 |
| Sankar, V | 1 |
| Prakash, S | 1 |
| Muthusamy, R | 1 |
| Krishnamurti, A | 1 |
| Surendran, S | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 4 |
| Nowak, P | 3 |
| Kostrzewa, RA | 1 |
| Skaba, D | 1 |
| Kostrzewa, RM | 2 |
| Ward, RJ | 1 |
| Colivicchi, MA | 1 |
| Allen, R | 1 |
| Schol, F | 1 |
| Lallemand, F | 1 |
| de Witte, P | 1 |
| Ballini, C | 1 |
| Corte, LD | 1 |
| Dexter, D | 1 |
| Sonsalla, PK | 3 |
| Wong, LY | 1 |
| Winnik, B | 1 |
| Buckley, B | 1 |
| Jaehne, EJ | 1 |
| Majumder, I | 1 |
| Salem, A | 1 |
| Irvine, RJ | 1 |
| Li, XM | 1 |
| Ma, HB | 1 |
| Ma, ZQ | 1 |
| Li, LF | 1 |
| Xu, CL | 1 |
| Qu, R | 1 |
| Ma, SP | 1 |
| Marcellino, D | 1 |
| Suárez-Boomgaard, D | 1 |
| Sánchez-Reina, MD | 1 |
| Aguirre, JA | 1 |
| Yoshitake, T | 1 |
| Yoshitake, S | 1 |
| Hagman, B | 1 |
| Kehr, J | 1 |
| Agnati, LF | 1 |
| Fuxe, K | 1 |
| Rivera, A | 1 |
| Reksidler, AB | 1 |
| Lima, MM | 1 |
| Dombrowski, PA | 1 |
| Barnabé, GF | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Vital, MA | 1 |
| Pierucci, M | 1 |
| Di Giovanni, G | 1 |
| Dragani, LK | 1 |
| Murzilli, S | 1 |
| Poggi, A | 1 |
| Kuroiwa, H | 1 |
| Yokoyama, H | 2 |
| Kimoto, H | 2 |
| Kato, H | 5 |
| Araki, T | 5 |
| Borah, A | 1 |
| Mohanakumar, KP | 1 |
| Muthian, G | 1 |
| Mackey, V | 1 |
| King, J | 1 |
| Charlton, CG | 1 |
| Shi, D | 1 |
| Lv, L | 1 |
| Li, L | 2 |
| Gu, P | 1 |
| Gao, J | 1 |
| Miao, Y | 1 |
| Hu, W | 1 |
| Shen, H | 1 |
| Harvey, BK | 1 |
| Chiang, YH | 1 |
| Pick, CG | 1 |
| Belin, AC | 2 |
| Westerlund, M | 2 |
| Anvret, A | 2 |
| Lindqvist, E | 2 |
| Pernold, K | 2 |
| Ogren, SO | 1 |
| Duester, G | 2 |
| Galter, D | 2 |
| Sgadò, P | 1 |
| Viaggi, C | 2 |
| Pinna, A | 1 |
| Marrone, C | 1 |
| Vaglini, F | 2 |
| Pontis, S | 1 |
| Mercuri, NB | 1 |
| Morelli, M | 1 |
| Corsini, GU | 2 |
| Zhou, C | 1 |
| Sun, K | 1 |
| Zhao, N | 1 |
| Sun, Y | 1 |
| Liu, X | 5 |
| Hibi, T | 1 |
| Liu, Z | 1 |
| Han, J | 1 |
| Bajo-Grañeras, R | 1 |
| Ganfornina, MD | 1 |
| Martín-Tejedor, E | 1 |
| Sanchez, D | 1 |
| Gao, L | 1 |
| Díaz-Martín, J | 1 |
| Dillmann, WH | 1 |
| López-Barneo, J | 1 |
| Bergstrom, BP | 1 |
| Sanberg, SG | 1 |
| Andersson, M | 1 |
| Mithyantha, J | 1 |
| Carroll, FI | 1 |
| Good, RL | 1 |
| Liang, LP | 1 |
| Patel, M | 1 |
| Radcliffe, RA | 1 |
| von Bothmer, A | 1 |
| Pum, ME | 2 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Langston, JW | 2 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 1 |
| Cruz, FC | 1 |
| Marin, MT | 1 |
| Leão, RM | 1 |
| Planeta, CS | 1 |
| Tu, ZC | 1 |
| Xu, XY | 1 |
| Li, R | 1 |
| Qu, WM | 1 |
| Urade, Y | 1 |
| Huang, ZL | 1 |
| Ueda, S | 2 |
| Ehara, A | 1 |
| Sakakibara, S | 1 |
| Yoshimoto, K | 2 |
| Hirata, K | 1 |
| Ran, C | 1 |
| Gellhaar, S | 1 |
| Lundströmer, K | 1 |
| Felder, MR | 1 |
| Jones, CK | 1 |
| Bubser, M | 1 |
| Thompson, AD | 1 |
| Dickerson, JW | 1 |
| Turle-Lorenzo, N | 1 |
| Amalric, M | 2 |
| Blobaum, AL | 1 |
| Bridges, TM | 1 |
| Morrison, RD | 1 |
| Jadhav, S | 1 |
| Engers, DW | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Daniels, JS | 1 |
| Lindsley, CW | 1 |
| Hopkins, CR | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Mattern, C | 1 |
| Silva, AM | 1 |
| Wessler, J | 1 |
| Ruocco, LA | 1 |
| van Bregt, DR | 1 |
| Thomas, TC | 1 |
| Hinzman, JM | 1 |
| Cao, T | 1 |
| Liu, M | 1 |
| Bing, G | 1 |
| Gerhardt, GA | 2 |
| Pauly, JR | 1 |
| Lifshitz, J | 1 |
| Meulendyke, KA | 1 |
| Pletnikov, MV | 1 |
| Engle, EL | 1 |
| Tarwater, PM | 1 |
| Graham, DR | 1 |
| Zink, MC | 1 |
| Kolik, LG | 1 |
| Kadnikov, IA | 1 |
| Zhukov, VN | 1 |
| Gudasheva, TA | 1 |
| Seredenin, SB | 1 |
| Wey, MC | 1 |
| Fernandez, E | 1 |
| Martinez, PA | 1 |
| Strong, R | 1 |
| Frank, T | 1 |
| Klinker, F | 1 |
| Falkenburger, BH | 1 |
| Laage, R | 2 |
| Lühder, F | 1 |
| Göricke, B | 2 |
| Schneider, A | 2 |
| Neurath, H | 1 |
| Desel, H | 1 |
| Liebetanz, D | 1 |
| Weishaupt, JH | 2 |
| Tanaka, K | 3 |
| Furuyashiki, T | 1 |
| Kitaoka, S | 1 |
| Senzai, Y | 1 |
| Imoto, Y | 1 |
| Segi-Nishida, E | 1 |
| Deguchi, Y | 1 |
| Breyer, RM | 1 |
| Breyer, MD | 1 |
| Narumiya, S | 1 |
| Schumm, S | 1 |
| Sebban, C | 1 |
| Cohen-Salmon, C | 1 |
| Callebert, J | 2 |
| Launay, JM | 2 |
| Golmard, JL | 1 |
| Boussicault, L | 1 |
| Petropoulos, I | 1 |
| Hild, A | 1 |
| Rousselet, E | 1 |
| Prigent, A | 1 |
| Friguet, B | 1 |
| Mariani, J | 1 |
| Brown, PL | 1 |
| Shepard, PD | 1 |
| Elmer, GI | 1 |
| Stockman, S | 1 |
| McFarland, R | 1 |
| Mayo, CL | 1 |
| Greenwald, M | 1 |
| Schoonover, C | 1 |
| Vogel, MW | 1 |
| Pelloux, Y | 1 |
| Dilleen, R | 1 |
| Economidou, D | 1 |
| Theobald, D | 1 |
| Everitt, BJ | 1 |
| Goldstein, N | 1 |
| Goldstein, R | 1 |
| Terterov, D | 1 |
| Kamensky, AA | 1 |
| Kovalev, GI | 1 |
| Zolotarev, YA | 1 |
| Avakyan, GN | 1 |
| Terterov, S | 1 |
| Choi, DY | 1 |
| Lee, MK | 1 |
| Hong, JT | 1 |
| Donsante, A | 1 |
| Brinster, LR | 1 |
| Kaler, SG | 1 |
| Lin, L | 1 |
| Meng, T | 1 |
| Liu, T | 1 |
| Zheng, Z | 1 |
| Boissonnet, A | 1 |
| Hévor, T | 1 |
| Landemarre, L | 1 |
| Cloix, JF | 1 |
| Han, F | 1 |
| Yu, H | 1 |
| Zheng, T | 1 |
| Ma, X | 1 |
| Zhao, X | 1 |
| Le, L | 1 |
| Su, Y | 2 |
| Zheng, QY | 1 |
| Meissner, W | 1 |
| Harnack, D | 1 |
| Paul, G | 1 |
| Reum, T | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Kupsch, A | 1 |
| Tillerson, JL | 4 |
| Cohen, AD | 3 |
| Caudle, WM | 2 |
| Zigmond, MJ | 5 |
| Schallert, T | 3 |
| Miller, GW | 4 |
| Breidert, T | 1 |
| Heneka, MT | 1 |
| Landreth, G | 1 |
| Doyle, SE | 1 |
| McIvor, WE | 1 |
| Menaker, M | 1 |
| Kurosaki, R | 1 |
| Muramatsu, Y | 1 |
| Michimata, M | 1 |
| Matsubara, M | 1 |
| Imai, Y | 2 |
| Itoyama, Y | 2 |
| Reverón, ME | 1 |
| Zafar, KS | 1 |
| Siddiqui, A | 1 |
| Sayeed, I | 1 |
| Ahmad, M | 2 |
| Salim, S | 1 |
| Islam, F | 3 |
| Lastres-Becker, I | 1 |
| de Miguel, R | 1 |
| De Petrocellis, L | 1 |
| Makriyannis, A | 1 |
| Di Marzo, V | 1 |
| Fernández-Ruiz, J | 3 |
| De la Fuente, M | 1 |
| Hernanz, A | 1 |
| Medina, S | 1 |
| Guayerbas, N | 1 |
| Fernández, B | 1 |
| Viveros, MP | 1 |
| Takahashi, A | 1 |
| Smith, AD | 1 |
| Schlüter, OM | 1 |
| Fornai, F | 2 |
| Alessandrí, MG | 1 |
| Takamori, S | 1 |
| Geppert, M | 1 |
| Jahn, R | 1 |
| Südhof, TC | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Höcht, C | 1 |
| Opezzo, JA | 1 |
| Gironacci, M | 1 |
| Peña, C | 1 |
| Taira, CA | 1 |
| Thiffault, C | 1 |
| Di Monte, DA | 1 |
| Burke, WJ | 1 |
| Li, SW | 1 |
| Williams, EA | 1 |
| Nonneman, R | 1 |
| Zahm, DS | 1 |
| Lonjon, M | 1 |
| Quentien, MH | 1 |
| Risso, JJ | 1 |
| Michiels, JF | 1 |
| Carre, E | 1 |
| Rostain, JC | 1 |
| Darbin, O | 1 |
| Battaglia, G | 1 |
| Busceti, CL | 1 |
| Molinaro, G | 1 |
| Biagioni, F | 1 |
| Storto, M | 1 |
| Nicoletti, F | 1 |
| Bruno, V | 1 |
| Legare, ME | 1 |
| Hanneman, WH | 1 |
| Alquicer, G | 1 |
| Silva-Gómez, AB | 1 |
| Peralta, F | 1 |
| Flores, G | 1 |
| Masini, CV | 1 |
| Holmes, PV | 1 |
| Freeman, KG | 1 |
| Maki, AC | 1 |
| Edwards, GL | 1 |
| Stephenson, G | 1 |
| Ben Shachar, D | 1 |
| Gluck, MR | 1 |
| Santana, LA | 1 |
| Granson, H | 1 |
| Yahr, MD | 1 |
| van Hierden, YM | 1 |
| de Boer, SF | 1 |
| Koolhaas, JM | 1 |
| Aubin, N | 1 |
| Barneoud, P | 1 |
| Carter, C | 1 |
| Caille, D | 1 |
| Sontag, N | 1 |
| Marc, C | 1 |
| Lolivier, J | 1 |
| Gardes, A | 1 |
| Perron, C | 1 |
| Le Kim, A | 1 |
| Charieras, T | 1 |
| Pandini, M | 1 |
| Burnier, P | 1 |
| Puech, F | 1 |
| Jegham, S | 1 |
| George, P | 1 |
| Scatton, B | 1 |
| Curet, O | 1 |
| Nakao, N | 1 |
| Shintani-Mizushima, A | 1 |
| Kakishita, K | 1 |
| Itakura, T | 1 |
| Wang, X | 2 |
| Lu, Y | 1 |
| Zhang, H | 1 |
| Wang, K | 1 |
| He, Q | 1 |
| Leng, A | 1 |
| Mura, A | 1 |
| Hengerer, B | 1 |
| Feldon, J | 2 |
| Ferger, B | 5 |
| Shukla, S | 2 |
| Agrawal, AK | 2 |
| Chaturvedi, RK | 2 |
| Seth, K | 2 |
| Srivastava, N | 2 |
| Sinha, C | 1 |
| Shukla, Y | 1 |
| Khanna, VK | 1 |
| Seth, PK | 1 |
| Pardini, C | 1 |
| Bartoli, C | 1 |
| Dinucci, D | 1 |
| Yuan, H | 2 |
| Sarre, S | 2 |
| Ebinger, G | 2 |
| Michotte, Y | 2 |
| Ogawa, N | 2 |
| Shimoji, M | 1 |
| Mandir, AS | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Miura, H | 1 |
| Qiao, H | 1 |
| Kitagami, T | 1 |
| Ohta, T | 1 |
| Ozaki, N | 1 |
| Orset, C | 1 |
| Parrot, S | 1 |
| Sauvinet, V | 1 |
| Cottet-Emard, JM | 1 |
| Bérod, A | 1 |
| Pequignot, JM | 1 |
| Denoroy, L | 1 |
| Shen, YQ | 1 |
| Hebert, G | 1 |
| Moze, E | 1 |
| Neveu, PJ | 1 |
| Li, KS | 1 |
| Lau, YS | 1 |
| Novikova, L | 1 |
| Roels, C | 1 |
| Gardian, G | 1 |
| Calingasan, NY | 2 |
| Yang, L | 2 |
| von Borstel, R | 1 |
| Saydoff, J | 1 |
| Browne, SE | 1 |
| Beal, MF | 5 |
| Jakobsen, B | 1 |
| Gramsbergen, JB | 1 |
| Møller Dall, A | 1 |
| Rosenblad, C | 3 |
| Zimmer, J | 1 |
| Asanuma, M | 1 |
| Miyazaki, I | 1 |
| Diaz-Corrales, FJ | 1 |
| Shimizu, M | 1 |
| Ahmad, AS | 1 |
| Ansari, MA | 1 |
| Saleem, S | 1 |
| Yousuf, S | 1 |
| Hoda, MN | 1 |
| de Lago, E | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Hu, LF | 1 |
| Zhou, F | 1 |
| Ding, JH | 1 |
| Dang, MT | 1 |
| Yokoi, F | 1 |
| McNaught, KS | 1 |
| Jengelley, TA | 1 |
| Jackson, T | 1 |
| Li, Y | 1 |
| Zbarsky, V | 1 |
| Datla, KP | 1 |
| Parkar, S | 1 |
| Rai, DK | 1 |
| Aruoma, OI | 1 |
| Dexter, DT | 1 |
| Finn, DP | 1 |
| Jhaveri, MD | 1 |
| Beckett, SR | 1 |
| Madjd, A | 1 |
| Kendall, DA | 1 |
| Marsden, CA | 1 |
| Chapman, V | 1 |
| Glaser, PE | 1 |
| Surgener, SP | 1 |
| Grondin, R | 1 |
| Gash, CR | 1 |
| Palmer, M | 1 |
| Castellanos, FX | 1 |
| Fitzsimmons, DF | 1 |
| Moloney, TC | 1 |
| Dowd, E | 1 |
| Hunt, DL | 1 |
| Yamoah, EN | 1 |
| Krubitzer, L | 1 |
| Sullivan, KA | 1 |
| Madl, JE | 1 |
| Legare, M | 1 |
| Tjalkens, RB | 1 |
| Meuer, K | 1 |
| Pitzer, C | 1 |
| Krüger, C | 1 |
| Peters, K | 1 |
| Schlachetzki, JC | 1 |
| Kobayashi, K | 1 |
| Dietz, GP | 1 |
| Weber, D | 1 |
| Schäbitz, WR | 1 |
| Bach, A | 1 |
| Schulz, JB | 1 |
| Ossowska, K | 1 |
| Smiałowska, M | 1 |
| Kuter, K | 1 |
| Wierońska, J | 1 |
| Zieba, B | 1 |
| Wardas, J | 1 |
| Dabrowska, J | 2 |
| Bortel, A | 2 |
| Biedka, I | 1 |
| Schulze, G | 1 |
| Rommelspacher, H | 1 |
| Liu, B | 1 |
| Dluzen, DE | 1 |
| Sava, V | 1 |
| Reunova, O | 1 |
| Velasquez, A | 1 |
| Sanchez-Ramos, J | 1 |
| Enna, SJ | 1 |
| Reisman, SA | 1 |
| Stanford, JA | 1 |
| Gardner, EL | 1 |
| Paredes, W | 1 |
| Giordano, A | 1 |
| Spector, J | 1 |
| Lepore, M | 1 |
| Wu, KM | 1 |
| Froimowitz, M | 1 |
| Rojo, AI | 2 |
| Montero, C | 1 |
| Salazar, M | 1 |
| Close, RM | 1 |
| Sánchez-González, MA | 1 |
| de Sagarra, MR | 2 |
| Jackson-Lewis, V | 2 |
| Cavada, C | 2 |
| Cuadrado, A | 2 |
| Chandler-Laney, PC | 1 |
| Castañeda, E | 1 |
| Viana, JB | 1 |
| Oswald, KD | 1 |
| Maldonado, CR | 1 |
| Boggiano, MM | 1 |
| Rodrigues, LG | 1 |
| Melo, P | 1 |
| Silva, MC | 1 |
| Tavares, MA | 1 |
| Landau, AM | 1 |
| Kouassi, E | 1 |
| Siegrist-Johnstone, R | 1 |
| Desbarats, J | 1 |
| Przedborski, S | 1 |
| Oswiecimska, J | 1 |
| Drosik, M | 1 |
| Kwiecinski, A | 1 |
| Opara, J | 1 |
| Brus, R | 1 |
| Baldwin, CM | 1 |
| Figueredo, AJ | 1 |
| Wright, LS | 1 |
| Wong, SS | 1 |
| Witten, ML | 1 |
| Struve, MF | 1 |
| McManus, BE | 1 |
| Wong, BA | 1 |
| Dorman, DC | 1 |
| Malkesman, O | 1 |
| Shayit, M | 1 |
| Genud, R | 1 |
| Zangen, A | 2 |
| Kinor, N | 2 |
| Maayan, R | 1 |
| Weizman, A | 1 |
| Weller, A | 2 |
| Yadid, G | 3 |
| Buck, K | 1 |
| Lavi-Avnon, Y | 1 |
| Finberg, JP | 1 |
| Gispan-Herman, I | 1 |
| Stern, Y | 1 |
| Schroeder, M | 1 |
| Gelber, V | 1 |
| Bergman, SY | 1 |
| Overstreet, DH | 2 |
| Meisner, F | 1 |
| Scheller, C | 1 |
| Kneitz, S | 1 |
| Sopper, S | 1 |
| Neuen-Jacob, E | 1 |
| Riederer, P | 3 |
| ter Meulen, V | 1 |
| Koutsilieri, E | 1 |
| Xie, JX | 1 |
| Wong, MS | 1 |
| Faulkner, AE | 1 |
| Yin, H | 1 |
| Schaeffel, F | 1 |
| Pozdeyev, N | 1 |
| Takagi, S | 1 |
| Watanabe, Y | 1 |
| Recchia, A | 1 |
| Rota, D | 1 |
| Debetto, P | 1 |
| Peroni, D | 1 |
| Guidolin, D | 1 |
| Negro, A | 1 |
| Skaper, SD | 1 |
| Giusti, P | 1 |
| Lorenzo, BJ | 1 |
| Rajeswari, A | 1 |
| Sabesan, M | 1 |
| Kadoguchi, N | 1 |
| Yano, R | 1 |
| Blanchet, J | 1 |
| Longpré, F | 1 |
| Bureau, G | 1 |
| DiPaolo, T | 1 |
| Bronchti, G | 1 |
| Martinoli, MG | 1 |
| Melamed, E | 2 |
| Hefti, F | 2 |
| Liebman, J | 1 |
| Schlosberg, AJ | 1 |
| Wurtman, RJ | 2 |
| Stricker, EM | 1 |
| Mefford, IN | 2 |
| Baker, TL | 1 |
| Boehme, R | 1 |
| Foutz, AS | 1 |
| Ciaranello, RD | 1 |
| Barchas, JD | 1 |
| Dement, WC | 2 |
| Schneider, MB | 1 |
| Murrin, LC | 1 |
| Pfeiffer, RF | 1 |
| Deupree, JD | 1 |
| Cooper, DR | 1 |
| Marrel, C | 1 |
| Testa, B | 1 |
| van de Waterbeemd, H | 1 |
| Quinn, N | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Rotrosen, J | 1 |
| Stanley, M | 1 |
| Kuhn, C | 1 |
| Wazer, D | 1 |
| Gershon, S | 1 |
| Jinnah, HA | 2 |
| Wojcik, BE | 1 |
| Hunt, M | 1 |
| Narang, N | 1 |
| Lee, KY | 1 |
| Goldstein, M | 1 |
| Wamsley, JK | 1 |
| Langlais, PJ | 1 |
| Friedmann, T | 2 |
| Bergqvist, PB | 1 |
| Vogels, BA | 1 |
| Bosman, DK | 1 |
| Maas, MA | 1 |
| Hjorth, S | 1 |
| Chamuleau, RA | 1 |
| Bengtsson, F | 1 |
| Moukhles, H | 1 |
| Nieoullon, A | 1 |
| Daszuta, A | 1 |
| Hadesman, R | 1 |
| Wiesner, RH | 1 |
| Go, VL | 1 |
| Tyce, GM | 1 |
| Pastuszko, A | 1 |
| Lajevardi, NS | 1 |
| Huang, CC | 1 |
| Tammela, O | 1 |
| Delivoria-Papadopoulos, M | 1 |
| Wilson, DF | 1 |
| Albanese, A | 1 |
| Granata, R | 1 |
| Gregori, B | 1 |
| Piccardi, MP | 1 |
| Colosimo, C | 1 |
| Tonali, P | 1 |
| Hossain, MA | 1 |
| Weiner, N | 1 |
| Rossetti, ZL | 1 |
| Lai, M | 1 |
| Hmaidan, Y | 1 |
| Gessa, GL | 1 |
| Hantraye, P | 1 |
| Brouillet, E | 1 |
| Ferrante, R | 1 |
| Palfi, S | 1 |
| Dolan, R | 1 |
| Matthews, RT | 1 |
| Dkhissi, O | 1 |
| Chanut, E | 1 |
| Versaux-Botteri, C | 1 |
| Minvielle, F | 1 |
| Trouvin, JH | 1 |
| Nguyen-Legros, J | 1 |
| Avraham, Y | 1 |
| Bonne, O | 1 |
| Berry, EM | 1 |
| King, D | 1 |
| Finlay, JM | 1 |
| Bowenkamp, KE | 1 |
| Lapchak, PA | 2 |
| Hoffer, BJ | 1 |
| Miller, PJ | 1 |
| Bickford, PC | 1 |
| Redmond, AM | 1 |
| Kelly, JP | 1 |
| Leonard, BE | 1 |
| Wachtel, SR | 1 |
| Bencsics, C | 1 |
| Kang, UJ | 1 |
| Boireau, A | 2 |
| Bordier, F | 1 |
| Dubédat, P | 1 |
| Pény, C | 1 |
| Impérato, A | 1 |
| Dluzen, D | 1 |
| Sasaki, K | 1 |
| Miyakawa, M | 1 |
| Sudo, T | 1 |
| Yoshizaki, F | 1 |
| Araujo, DM | 1 |
| Hilt, DC | 1 |
| Sheng, J | 1 |
| Jiao, S | 1 |
| Naoi, M | 1 |
| Maruyama, W | 1 |
| Kasamatsu, T | 1 |
| Dostert, P | 1 |
| Jentsch, JD | 1 |
| Taylor, JR | 1 |
| Roth, RH | 1 |
| Horger, BA | 1 |
| Nishimura, MC | 1 |
| Armanini, MP | 1 |
| Wang, LC | 1 |
| Poulsen, KT | 1 |
| Kirik, D | 2 |
| Moffat, B | 1 |
| Simmons, L | 1 |
| Johnson, E | 1 |
| Milbrandt, J | 1 |
| Rosenthal, A | 1 |
| Bjorklund, A | 3 |
| Vandlen, RA | 1 |
| Hynes, MA | 1 |
| Phillips, HS | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Blanchet, PJ | 1 |
| Konitsiotis, S | 1 |
| Hyland, K | 1 |
| Arnold, LA | 1 |
| Pettigrew, KD | 1 |
| Chase, TN | 1 |
| Inoue, K | 1 |
| Kiriike, N | 1 |
| Okuno, M | 1 |
| Fujisaki, Y | 1 |
| Kurioka, M | 1 |
| Iwasaki, S | 1 |
| Yamagami, S | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Carlson, JD | 1 |
| Pearlstein, RD | 1 |
| Buchholz, J | 1 |
| Iacono, RP | 1 |
| Maeda, G | 1 |
| Scearce-Levie, K | 1 |
| Chen, JP | 1 |
| Gardner, E | 1 |
| Hen, R | 2 |
| Earl, CD | 1 |
| Kuschinsky, K | 1 |
| Oertel, WH | 1 |
| Andreassen, OA | 2 |
| Ferrante, RJ | 2 |
| Dedeoglu, A | 2 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Aikawa, M | 1 |
| Ishizuya-Oka, A | 1 |
| Yamaoka, S | 1 |
| Koibuchi, N | 1 |
| Reader, TA | 2 |
| Ase, AR | 2 |
| Le Marec, N | 1 |
| Lalonde, R | 1 |
| Ben, V | 1 |
| Blin, O | 1 |
| Bruguerolle, B | 1 |
| Heim, C | 1 |
| Zhang, J | 1 |
| Lan, J | 1 |
| Sieklucka, M | 1 |
| Kurz, T | 1 |
| Gerlach, M | 2 |
| Sontag, KH | 1 |
| Uehara, T | 1 |
| Tanii, Y | 1 |
| Sumiyoshi, T | 1 |
| Kurachi, M | 1 |
| Puglisi-Allegra, S | 2 |
| Cabib, S | 2 |
| Pascucci, T | 1 |
| Ventura, R | 2 |
| Cali, F | 1 |
| Romano, V | 1 |
| Murphy, CA | 1 |
| Pezze, M | 1 |
| Heidbreder, C | 1 |
| Ste-Marie, L | 1 |
| Vachon, P | 1 |
| Vachon, L | 1 |
| Bémeur, C | 1 |
| Guertin, MC | 1 |
| Montgomery, J | 1 |
| Ongali, B | 1 |
| Hébert, C | 1 |
| Amdiss, F | 1 |
| Xue, YL | 1 |
| Wang, ZF | 1 |
| Zhong, DG | 1 |
| Cui, X | 1 |
| Li, XJ | 1 |
| Ma, XJ | 1 |
| Wang, LN | 1 |
| Zhu, K | 1 |
| Sun, AM | 1 |
| Bezard, E | 2 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Bloch, B | 1 |
| Gross, CE | 2 |
| Nash, JE | 1 |
| Brotchie, JM | 2 |
| Nir, I | 1 |
| Imam, SZ | 1 |
| Itzhak, Y | 2 |
| Slikker, W | 2 |
| Ali, SF | 4 |
| Costa, G | 1 |
| Abin-Carriquiry, JA | 1 |
| Dajas, F | 1 |
| Albers, DW | 1 |
| Carlson, EJ | 1 |
| Epstein, CJ | 1 |
| Hofele, K | 1 |
| Sedelis, M | 1 |
| Auburger, GW | 1 |
| Morgan, S | 1 |
| Schwarting, RK | 1 |
| Zhuang, X | 1 |
| Oosting, RS | 1 |
| Jones, SR | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Chen, JF | 1 |
| Xu, K | 1 |
| Petzer, JP | 1 |
| Staal, R | 1 |
| Xu, YH | 1 |
| Beilstein, M | 1 |
| Castagnoli, K | 1 |
| Castagnoli, N | 1 |
| Schwarzschild, MA | 1 |
| Pestana, M | 1 |
| Jardim, H | 1 |
| Correia, F | 1 |
| Vieira-Coelho, MA | 1 |
| Soares-da-Silva, P | 1 |
| Philhower, J | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Nishino, S | 1 |
| Fujiki, N | 1 |
| Ripley, B | 1 |
| Sakurai, E | 1 |
| Kato, M | 1 |
| Watanabe, T | 1 |
| Mignot, E | 1 |
| Yanai, K | 1 |
| Barthwal, MK | 1 |
| Dikshit, M | 1 |
| Rebec, GV | 1 |
| Barton, SJ | 1 |
| Ennis, MD | 1 |
| Visser, JE | 1 |
| Smith, DW | 1 |
| Moy, SS | 1 |
| Breese, GR | 1 |
| Rothstein, JD | 1 |
| Burger, C | 1 |
| Lundberg, C | 1 |
| Johansen, TE | 1 |
| Muzyczka, N | 1 |
| Mandel, RJ | 1 |
| Binienda, ZK | 1 |
| Pereira, F | 1 |
| Alper, K | 1 |
| Pacak, K | 1 |
| Armando, I | 1 |
| Fukuhara, K | 1 |
| Kvetnansky, R | 1 |
| Palkovits, M | 1 |
| Kopin, IJ | 1 |
| Miller, JD | 1 |
| Faull, KF | 1 |
| Bowersox, SS | 1 |
| Gurguis, GN | 1 |
| Klein, E | 1 |
| Uhde, TW | 1 |
| Russ, H | 2 |
| Mihatsch, W | 1 |
| Przuntek, H | 2 |
| Johansson, PE | 1 |
| Terenius, L | 1 |
| Häggström, JE | 1 |
| Gunne, L | 1 |
| Date, I | 1 |
| Felten, DL | 1 |
| Felten, SY | 1 |
| Chen, M | 1 |
| Kuang, A | 1 |
| Horellou, P | 1 |
| Marlier, L | 1 |
| Privat, A | 1 |
| Darchen, F | 1 |
| Scherman, D | 1 |
| Henry, JP | 1 |
| Mallet, J | 1 |
| Takeda, N | 1 |
| Morita, M | 1 |
| Yamatodani, A | 1 |
| Wada, H | 1 |
| Matsunaga, T | 1 |
| Murphy, JM | 1 |
| McBride, WJ | 1 |
| Lumeng, L | 1 |
| Li, TK | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Perry, TL | 1 |
| Yong, VW | 1 |
| Ito, M | 1 |
| Jones, K | 1 |
| Wall, RA | 1 |
| Foulks, JG | 1 |
| Wright, JM | 1 |
| Kish, SJ | 1 |
| Isacson, O | 1 |
| Gage, FH | 1 |
| Rodríguez-Puyol, D | 1 |
| Alsasua, A | 1 |
| Santos, JC | 1 |
| Blanchart, A | 1 |
| López-Novoa, JM | 1 |
| Eidelberg, E | 1 |
| Brooks, BA | 1 |
| Morgan, WW | 1 |
| Walden, JG | 1 |
| Kokemoor, RH | 1 |
| Heikkila, RE | 1 |
| Sershen, H | 1 |
| Hashim, A | 1 |
| Lajtha, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment With Lorcaserin for Cocaine Use: The TLC Study[NCT03192995] | Phase 2 | 22 participants (Actual) | Interventional | 2018-01-01 | Terminated (stopped due to FDA alert regarding study drug safety) | ||
| The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms[NCT04336228] | Phase 4 | 48 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the adherence of lorcaserin vs. placebo, the investigators measured adherence as the frequency of taking the study drug as measured by the number of MEMS cap openings (wireless medication monitoring devices that record each opening as a real-time medication event). Cumulative percent adherence was calculated by dividing the frequency of openings at a given time point divided by the number of days since baseline. (NCT03192995)
Timeframe: 12 weeks
| Intervention | percent adherence (Mean) |
|---|---|
| Experimental | 51.6 |
| Control | 66.2 |
To determine the feasibility of retaining individuals on lorcaserin vs. placebo, the investigators have calculated the mean weekly percentage of follow-up visits of those randomized in the study (NCT03192995)
Timeframe: 12 weeks
| Intervention | mean percent of visit retention (Mean) | |
|---|---|---|
| Treatment Group | Control Group | |
| Mean Percent of Weekly Follow-up Visits by Treatment and Control Arms | 83 | 81 |
The outcome measure determines the proportion of self-reported past week cocaine use by Time-Line-Follow-back (TLFB) among lorcaserin and placebo groups at Baseline and at 12 weeks. (NCT03192995)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Proportion of self-reported weekly cocaine use by Time-Line-Follow-Up (TLFU) at baseline | Proportion of self-reported weekly cocaine use by TLFU at Week 12 | |
| Control | 6 | 6 |
| Experimental | 12 | 7 |
The outcome measure determines the proportion of urine-positive samples with cocaine positivity among lorcaserin and placebo groups at Baseline and at Week 12 (NCT03192995)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Urine positive samples with cocaine use at baseline | Urine positive samples with cocaine use at Week 12 | |
| Control | 0 | 1 |
| Treatment | 8 | 7 |
1 review available for 3,4-dihydroxyphenylacetic acid and Disease Models, Animal
| Article | Year |
|---|---|
Renal dopaminergic mechanisms in renal parenchymal diseases and hypertension.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blood Pressure; Disease Models, Animal; Dopamine; Homovanil | 2001 |
1 trial available for 3,4-dihydroxyphenylacetic acid and Disease Models, Animal
| Article | Year |
|---|---|
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transpla | 2004 |
299 other studies available for 3,4-dihydroxyphenylacetic acid and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Melanopsin modulates refractive development and myopia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Axial Length, Eye; Cornea; Disease Models, Animal; Dopamine | 2022 |
[Effect of Rehmanniae Radix on depression-like behavior and hippocampal monoamine neurotransmitters of chronic unpredictable mild stress model rats].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Chromatography, Liquid; Depression; | 2022 |
Effects of artificial light with different spectral composition on eye axial growth in juvenile guinea pigs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Eye; Guinea Pigs; Light; | 2023 |
A Mixture of Phenolic Metabolites of Quercetin Can Decrease Elevated Blood Pressure of Spontaneously Hypertensive Rats Even in Low Doses.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antihypertensive Agents; Biological Availability; Blood Pre | 2020 |
Protective Effect of Hemin Against Experimental Chronic Fatigue Syndrome in Mice: Possible Role of Neurotransmitters.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Behavior, Animal; Brain; Disease Models, Animal; D | 2020 |
Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Line; Cell Line, Tumor; | 2020 |
Effects of a high-fat-diet supplemented with probiotics and ω3-fatty acids on appetite regulatory neuropeptides and neurotransmitters in a pig model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Appetite Regulation; Diet, High-Fat; Dietary Supplements; D | 2020 |
A novel idea for establishing Parkinson's disease mouse model by intranasal administration of paraquat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Corpus Striatum; Disease Models | 2021 |
Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Dopa | 2021 |
Depressive-like behaviors in mice with Imiquimod-induced psoriasis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; | 2020 |
Antidepressant-Like Effect of the Endogenous Neuroprotective Amine, 1MeTIQ in Clonidine-Induced Depression: Behavioral and Neurochemical Studies in Rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biogenic Monoamines; Brain; Brain Che | 2017 |
Assessment of gait dynamics in rotenone-induced rat model of Parkinson's disease by footprint method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 2017 |
Effect of Progressive Heart Failure on Cerebral Hemodynamics and Monoamine Metabolism in CNS.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basilar Artery; Brain; Brain Chemistry; Carotid Arteries; C | 2017 |
Trace amine-associated receptor 1 regulation of methamphetamine-induced neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Body Temperature Regulation; Brain; Ce | 2017 |
Myopia induced by flickering light in guinea pig eyes is associated with increased rather than decreased dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Axial Length, Eye; Blotting, Western; Chromatography, High | 2017 |
Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Central Nervous System; Disease Models, An | 2018 |
TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; | 2018 |
Peripheral Administration of Tetanus Toxin Hc Fragment Prevents MPP
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2018 |
Light rescues circadian behavior and brain dopamine abnormalities in diurnal rodents exposed to a winter-like photoperiod.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Chromatography, High Pressure | 2018 |
Aβ dimers induce behavioral and neurochemical deficits of relevance to early Alzheimer's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Animals; Be | 2018 |
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Two flavonoid metabolites, 3,4-dihydroxyphenylacetic acid and 4-methylcatechol, relax arteries ex vivo and decrease blood pressure in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antihypertensive Agents; Aorta, Thoracic; Arterial Pressure | 2018 |
Dopamine Receptor Subtypes Mediate Opposing Effects on Form Deprivation Myopia in Pigmented Guinea Pigs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Models, Anima | 2018 |
Curcumin restores rotenone induced depressive-like symptoms in animal model of neurotoxicity: assessment by social interaction test and sucrose preference test.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Choice Behavior; Corpus Striatum; Curcumi | 2019 |
Lack of cone mediated retinal function increases susceptibility to form-deprivation myopia in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Models, Anima | 2019 |
Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Disease Models, Animal; Dopamine; D | 2019 |
Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cognition; Disease Models, Animal; Dopamine; Emotions; Male | 2019 |
Morphological and metabolic changes in the nigro-striatal pathway of synthetic proteasome inhibitor (PSI)-treated rats: a MRI and MRS study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Magnetic | 2013 |
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Count; Cells, Cultured; Disease Models, Animal; Dopami | 2013 |
Systems analysis of genetic variation in MPTP neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Brain; Disease Models, Animal; Dopamine; Gene E | 2013 |
CREB phosphorylation regulates striatal transcriptional responses in the self-administration model of methamphetamine addiction in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Stimulants; Conditioning, Operant; C | 2013 |
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz | 2013 |
Assessment of the abuse potential of MDMA in the conditioned place preference paradigm: role of CB1 receptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Conditioning, Operant; Disease | 2013 |
Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acyclic Monoterpenes; | 2013 |
The rat with oxygen-induced retinopathy is myopic with low retinal dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Blotting, Western; Chromatography, High P | 2013 |
The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Biogenic Monoamines; Chromatography, Hig | 2014 |
Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Disease Models, Animal; Dopamin | 2014 |
Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; alpha-Synuclein; Amyloid; Animals; Corpu | 2014 |
Predator exposure/psychosocial stress animal model of post-traumatic stress disorder modulates neurotransmitters in the rat hippocampus and prefrontal cortex.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cats; Disease Models, Animal; Hippocampus; Homovanillic Aci | 2014 |
Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Carrier Proteins; Cell Line; Cell Survival; Dis | 2014 |
Acute pancreatitis affects the metabolism of catecholamine neurotransmitters in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acute Disease; Animals; Catecholamines; Cerebellum; Corpus Striatum; | 2014 |
Dysregulation of dopaminergic regulatory mechanisms in the mesolimbic pathway induced by morphine and morphine withdrawal.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Disease Models, Animal; Dopamine; Gen | 2015 |
Dietary supplementation with resveratrol protects against striatal dopaminergic deficits produced by in utero LPS exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dietary Supplements; Disease Models, Anima | 2014 |
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2014 |
PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Biolo | 2015 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; | 2015 |
Visually-driven ocular growth in mice requires functional rod photoreceptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Models, Anima | 2014 |
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Mo | 2014 |
(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2014 |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do | 2015 |
Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitor | 2014 |
Dietary long chain n-3 polyunsaturated fatty acids prevent impaired social behaviour and normalize brain dopamine levels in food allergic mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chymases; Diet; Disease Models, Animal; Docosahexaen | 2015 |
The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2015 |
Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Clioquinol; Dementia; Disease Models, Animal; Dopami | 2015 |
Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Di | 2015 |
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer | 2016 |
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; DNA | 2015 |
Neuroprotective effects of 3-O-demethylswertipunicoside against MPTP-induced Parkinson's disease in vivo and its antioxidant properties in vitro.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biphenyl Comp | 2015 |
Neonatal aphakia is associated with altered levels of dopamine metabolites in the non-human primate retina.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Aphakia, Postcataract; Axial Length, Eye; | 2015 |
Memory enhancement by Tamoxifen on amyloidosis mouse model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Corp | 2016 |
Evidence for a role of adaptive immune response in the disease pathogenesis of the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adaptive Immunity; Ana | 2016 |
Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amyotrophic Lateral Sclerosis; Animals; Biogenic Monoamines; Corpus | 2016 |
Interaction between handling induced stress and anxiolytic effects of ethanol in zebrafish: A behavioral and neurochemical analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Chromatograp | 2016 |
Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Alcohol Abstinence; Alcoholism; Animals; Benzazepines; | 2016 |
Analysis of anti-depressant potential of curcumin against depression induced male albino wistar rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Avoidance Learning; Behavior, Animal | 2016 |
Characterization of cognitive impairments and neurotransmitter changes in a novel transgenic mouse lacking Slc10a4.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Brain; Chromatography, High Pressure Liquid; | 2016 |
Physical exercise counteracts MPTP-induced changes in neural precursor cell proliferation in the hippocampus and restores spatial learning but not memory performance in the water maze.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Bromodeoxyuri | 2016 |
Alteration of catecholamine concentrations in rat testis after methamphetamine exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Chromatography, High Pressur | 2017 |
MPTP neurotoxicity is highly concordant between the sexes among BXD recombinant inbred mouse strains.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2016 |
Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Auditory Perception; Corpus Striatum; DiGeorge Syndr | 2017 |
Altered Refractive Development in Mice With Reduced Levels of Retinal Dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Biomarkers; Disease Models, Animal; Disease Progress | 2016 |
IRBP deficiency permits precocious ocular development and myopia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Axial Length, Eye; Disease Models, Animal; Dopamine; Eye; E | 2016 |
Irradiation in adulthood as a new model of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids; Animals; Behavior, Animal; Disease Models, Animal; Dopa | 2008 |
Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; | 2008 |
Significant effect of dimethylsulfoniopropionate on Parkinson's disease of senescence-accelerated mice induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Alzheimer Disea | 2008 |
Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorocebus aethiops; Corpus Striatum; Di | 2008 |
[Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Central Nervous System Agents; Corpus Str | 2008 |
Dopamine and serotonin release in the nucleus accumbens during starvation-induced hyperactivity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Body Temperature; Body Weight; Chroma | 2009 |
Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Antipsychotic Agents; Brain Chemistry; Disease | 2010 |
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liq | 2009 |
Cognitive impairment of prefrontal-dependent decision-making in rats after the onset of chronic pain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Chronic Disease; Cognition; Decision Making; Dise | 2009 |
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma | 2009 |
Behavioral and neurochemical profile of m-CPP following exposure to single restraint stress in rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pre | 2009 |
Prenatal methamphetamine exposure affects the mesolimbic dopaminergic system and behavior in adult offspring.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Disease Mod | 2009 |
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain Chemistry; Cell Division; Chrom | 2010 |
Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Glutathione; Glutathione | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 2010 |
Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcoholism; Amino Acids; Animals; Biogenic Monoamines; Conditioning, | 2009 |
The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antioxidants; Corpus Striatum; Diseas | 2010 |
Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Arousal; Body Temperature Regulation; Brain; Cerebral Corte | 2011 |
Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Cor | 2010 |
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count; | 2010 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2009 |
Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carotenoids; Disease Models, Animal; Dopamine; Functional L | 2009 |
Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; C | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2010 |
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth | 2010 |
The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson's disease rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antigens, CD; Corpus Striatum; Diseas | 2011 |
Methamphetamine potentiates behavioral and electrochemical responses after mild traumatic brain injury in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Injuries; Corpus Striatum; Disease Models, Animal; Do | 2011 |
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; A | 2011 |
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Analysis of Variance; Animals; Behavior, Animal; Brain | 2011 |
Effects of dihydroxylphenyl lactic acid on inflammatory responses in spinal cord injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents; Disease Models, Animal; I-kappa B | 2011 |
Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Apolipoproteins D; Apoptosis; Astrocytes; | 2011 |
Heat shock protein 70 kDa over-expression and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal degeneration in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2011 |
Functional reorganization of the presynaptic dopaminergic terminal in parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Chromatography, Hi | 2011 |
Mouse strain- and age-dependent effects of binge methamphetamine on dopaminergic signaling.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Amphetamine-Related Disorders; Animals; Basal Ganglia; | 2011 |
Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exacerbates [corrected] parkinsonian symptoms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Res | 2011 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Stress-induced cross-sensitization to amphetamine is related to changes in the dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Amphetamines; Analysis of Variance; Animals; Animals, N | 2012 |
Acute administration of fluoxetine normalizes rapid eye movement sleep abnormality, but not depressive behaviors in olfactory bulbectomized rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antidepressive Agents, Second-Generat | 2012 |
Neuroprotective effects of melatonin on the nigrostriatal dopamine system in the zitter rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Cytokines; Disease Models, Animal; Dopamin | 2012 |
Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Analysis of Variance; Animals; Apomorphine; C | 2012 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Anima | 2012 |
Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atrophy; Brain Injuries; Calcium-Binding Proteins; Carrier | 2012 |
Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; AIDS Dementia Complex; Animals; Blotting, Western; Chromatography, H | 2012 |
[Effect of GB-115 dipeptide on anxiety in rats with model benzodiazepine withdrawal syndrome].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Outbred Strains; Anti-Anxiety Agents; Anxiety Diso | 2011 |
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Body Weight; Cognition Disorders; C | 2012 |
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma | 2012 |
Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzazepines; Calcium-Binding Protein | 2012 |
Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Age Factors; Aging; An | 2012 |
Altered spatial learning, cortical plasticity and hippocampal anatomy in a neurodevelopmental model of schizophrenia-related endophenotypes.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cytarabine; Disease Models, Animal; Dopamine; Endophenotype | 2012 |
Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Behavior, Addictive; Cocaine; Cond | 2012 |
Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Behavior, Addictive; Cocaine; Cond | 2012 |
Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Behavior, Addictive; Cocaine; Cond | 2012 |
Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Behavior, Addictive; Cocaine; Cond | 2012 |
Blood-brain barrier unlocked.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Blood-Brain Barrier; Catalepsy; | 2012 |
Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neuro | 2013 |
L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Triphosphatases; Animals; Antiparkinson Agents; Blood-Brai | 2013 |
Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Data | 2013 |
Monoamines and glycogen levels in cerebral cortices of fast and slow methionine sulfoximine-inbred mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Disease Models, Animal; Glycoge | 2013 |
Otoprotective effects of erythropoietin on Cdh23erl/erl mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Analysis of Variance; Animals; Auditory Thresh | 2013 |
Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Death; Disease Models, Animal; Dopamine; Electric Stim | 2002 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; | 2002 |
Circadian rhythmicity in dopamine content of mammalian retina: role of the photoreceptors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Circadian Rhythm; Dis | 2002 |
Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; C | 2002 |
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus | 2002 |
Dose-dependent protective effect of selenium in rat model of Parkinson's disease: neurobehavioral and neurochemical evidences.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Ascorbic Acid; Behavior, Animal; Brain; Disea | 2003 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can | 2003 |
Characterization of monoaminergic systems in brain regions of prematurely ageing mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging, Premature; Animals; Brain; Disease Models, Animal; Dopamine; | 2003 |
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, An | 2003 |
Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Casts, Surgical; Corpus Stri | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; | 2003 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Study of the hypothalamic angiotensin system in aortic coarctated rats using the reverse microdialysis technique.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor | 2003 |
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2003 |
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2003 |
Alteration of striatal dopaminergic function induced by glioma development: a microdialysis and immunohistological study in the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Afferent Pathways; Animals; Brain Neoplasms; Disease Models, Animal; | 2004 |
Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic | 2004 |
Genetic, biochemical, and characterization of neurological mutant 3, a new mouse model for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Chromosome Mapping; Disease Models, Animal | 2003 |
Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animals, Newborn; Behavior, Animal; Denervation; Dis | 2004 |
Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; Explorator | 2004 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine; | 2004 |
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; | 2004 |
The control of feather pecking by serotonin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Brain; Brain Chemistry; Chick | 2004 |
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzophenones; Brain; Corpus Striatum; Disease Models, Anim | 2004 |
Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Differentiation; Cell Division; Cell | 2004 |
Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; | 2004 |
Co-transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6-hydroxydopamine-lesioned rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Binding, Competitive; Brain Tissue Transplantation; Carotid | 2004 |
Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allyl Compounds; Anima | 2004 |
Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressur | 2004 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Dis | 2005 |
Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Anima | 2005 |
Effects of fluvoxamine on levels of dopamine, serotonin, and their metabolites in the hippocampus elicited by isolation housing and novelty stress in adult rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Exploratory Behavior; Flu | 2005 |
Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Ce | 2005 |
Dopamine transporters are involved in the onset of hypoxia-induced dopamine efflux in striatum as revealed by in vivo microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Corpus Striatum; Disease Models, | 2005 |
In mice, production of plasma IL-1 and IL-6 in response to MPTP is related to behavioral lateralization.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus | 2005 |
MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Apoptosis; Bl | 2005 |
Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetates; Animals; Die | 2004 |
Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Pro | 2005 |
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones; | 2005 |
Neuroprotection by crocetin in a hemi-parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Carotenoids; Catala | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Effects of iptakalim on extracellular glutamate and dopamine levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 2006 |
Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Brain; Chromatography, High Pressure Liquid; | 2005 |
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; F | 2005 |
Behavioral, central monoaminergic and hypothalamo-pituitary-adrenal axis correlates of fear-conditioned analgesia in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analgesia; Animals; Behavior, Animal; Biogenic Monoamines; Brain; Co | 2006 |
Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatogra | 2006 |
Multisensory plasticity in congenitally deaf mice: how are cortical areas functionally specified?
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Animals; Brain Mapping; Calcium-Transporting A | 2006 |
Manganese-induced neurotoxicity: the role of astroglial-derived nitric oxide in striatal interneuron degeneration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Brain; Disease Models, Animal; Dopamine; Female | 2006 |
Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Nor | 2006 |
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Chromatography, High Pre | 2006 |
Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Corpus Striatum; Disease Mode | 2006 |
Can low level exposure to ochratoxin-A cause parkinsonism?
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Age of Onset; Animals; Antioxidants; Carcinogens; Corpu | 2006 |
CGP 56999A, a GABA(B) receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Corpus Striatum; Denerva | 2006 |
A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Cocaine; Dialysis; | 2006 |
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; | 2006 |
A history of human-like dieting alters serotonergic control of feeding and neurochemical balance in a rat model of binge-eating.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Second-Generation; Brain; Bulimia; D | 2007 |
Effects of postnatal exposure to methamphetamine on the development of the rat retina.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Size; Disease Models, Animal; Dopamine; Female; Male; | 2006 |
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Depressants; Chromatography, High Pr | 2007 |
Protocol for the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 2007 |
Amphetamine and mCPP effects on dopamine and serotonin striatal in vivo microdialysates in an animal model of hyperactivity.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,6-Dihydroxytryptamine; Age Factors; Amphetamine; Animals; Attentio | 2007 |
Repeated aerosol-vapor JP-8 jet fuel exposure affects neurobehavior and neurotransmitter levels in a rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Inhalation; Aerosols; Air Pollutants, Occupational; | 2007 |
Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; gamma-Amin | 2007 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Dehydroepiandrosterone in the nucleus accumbens is associated with early onset of depressive-behavior: a study in an animal model of childhood depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Animals; Biogenic Monoamines; Child; Dehydroepiandrost | 2007 |
Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Behavior, Animal; Ben | 2008 |
The reward system and maternal behavior in an animal model of depression: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Animals, Newborn; Behavior, Animal; Body Weigh | 2008 |
Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain-Derived Neurotrophic Factor; Disease Models, A | 2008 |
Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
High susceptibility to experimental myopia in a mouse model with a retinal on pathway defect.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Models, Anima | 2008 |
Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Cytoprotectio | 2008 |
Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromodeoxyuridine; Cell Differentiation; Coculture Techniqu | 2008 |
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; A | 2008 |
Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi | 2008 |
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Animals, Newborn; Cell Count; Disease | 2008 |
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dop | 1980 |
Parkinson's disease: studies with an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology; | 1984 |
Narcolepsy: biogenic amine deficits in an animal model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Disease Models, Animal; Dogs; Dopamine; Ep | 1983 |
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovani | 1980 |
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dop | 1984 |
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 1984 |
Experimental dystonia induced by quaternary-chlorpromazine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disease | 1980 |
Dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; Caudate Nucleus; Disease Models, Animal; Dopa | 1994 |
Neocortical dialysate monoamines of rats after acute, subacute, and chronic liver shunt.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acute Disease; Amino Acids; Ammonia; Animals; Biogenic Monoamines; B | 1995 |
Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal | 1995 |
Concentrations of 3,4-dihydroxyphenylalanine and catecholamines and metabolites in brain in an anhepatic model of hepatic encephalopathy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Catecholamines; Dihydroxyphenylalan | 1995 |
Levels of dopamine and its metabolites in the extracellular medium of the striatum of newborn piglets during graded hypoxia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Corpus Striatum; Disease Models, Animal; | 1994 |
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 1993 |
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyc | 1993 |
Depletion of mesolimbic dopamine during behavioral despair: partial reversal by chronic imipramine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Depression; Disease Models, Animal; Dopami | 1993 |
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Model | 1996 |
Changes in retinal dopaminergic cells and dopamine rhythmic metabolism during the development of a glaucoma-like disorder in quails.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Count; Chromatography, High Pressure Liquid; Circadian | 1996 |
Behavioral and neurochemical alterations caused by diet restriction--the effect of tyrosine administration in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anorexia Nervosa; Brain; Cognition; Diet, Reducing; Disease | 1996 |
Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Age | 1997 |
Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dis | 1997 |
Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Depressive Disorder; Disease Models, Anim | 1997 |
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell | 1997 |
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1997 |
Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Estradio | 1997 |
[Evaluation of marble burying behavior: induced alteration of monoamine metabolism in mouse brain].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Disease Models, Animal; Dopamin | 1997 |
Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; Apomorphine; Behavior, Animal; Disease Models | 1997 |
Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and neuroprotection by endogenous catechol isoquinolines.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Cycloheximide; Disease Model | 1998 |
Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Brain; Dextroamphetamine; Disease Mod | 1998 |
Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Mo | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; B | 1998 |
Prefrontal and striatal dopamine metabolism during enhanced rebound hyperphagia induced by space restriction--a rat model of binge eating.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bulimia; Chromatography, High Pressure Liquid; Disease Mode | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antimetabolites; Basal Ganglia Diseases; Cerebral Cortex; D | 1999 |
5-HT receptor knockout mice: pharmacological tools or models of psychiatric disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aggression; Animals; Behavior, Animal; Cocaine; Disease Models, Anim | 1999 |
Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma | 1999 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Antibodies; Disease Models, Animal; Dopamine; Free R | 2000 |
Differential effects of L-trytophan and buspirone on biogenic amine contents and metabolism in Lurcher mice cerebellum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Buspirone; Cerebellar Ataxia; Cerebellum; | 2000 |
Time-dependent striatal dopamine depletion after injection of 6-hydroxydopamine in the rat. Comparison of single bilateral and double bilateral lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Dise | 1999 |
Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspartic Acid; Carotid Stenosis; Cognition Disorders; Corpu | 2000 |
Neonatal lesions of the left entorhinal cortex affect dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Animals, Newborn; Brain; Caudate Nucleus; Disease | 2000 |
Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Biogenic Monoamines; Brain; Caudate Nucleus; Dise | 2000 |
Differential involvement of dopamine in the shell and core of the nucleus accumbens in the expression of latent inhibition to an aversively conditioned stimulus.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Avoidance Learning; Behavior, Animal; Conditioning, Psychol | 2000 |
Hydroxyl radical production in the cortex and striatum in a rat model of focal cerebral ischemia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Body Temperature; Cerebral Cortex; Cerebrovascular Circulat | 2000 |
Dopamine D(1) and D(2) receptors in the forebrain of dystonia musculorum mutant mice: an autoradiographic survey in relation to dopamine contents.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Cerebellar Ataxia; Disease M | 2000 |
Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenal Medulla; Animals; Antiparkinson Agents; Apomorphine; Capsule | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Corpus Striatum; Cyclic AMP; Disease | 2000 |
Diurnal metabolism of dopamine in dystrophic retinas of homozygous and heterozygous retinal degeneration slow (rds) mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Circadian Rhythm; Disease Models, Animal; Dopa | 2000 |
Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implications for the prevention of methamphetamine-induced neurotoxic damage.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; | 2000 |
Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Area Under Curve; Body Temperature; Central Nervous | 2000 |
Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chlorisondamine; Corpus Striatum; Disease Models, Animal; D | 2001 |
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Prote | 2001 |
Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2001 |
Hyperactivity and impaired response habituation in hyperdopaminergic mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamines; Animals; Apomorphine; Attention Deficit Disorder with | 2001 |
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non- | 2001 |
Limbic dopaminergic adaptation to a stressful stimulus in a rat model of depression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adaptation, Physiological; Animals; Depression; Disease Models, Anim | 2001 |
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat | 2001 |
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur | 2001 |
Opposite genotype-dependent mesocorticolimbic dopamine response to stress.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Depression; Disease Models, Animal; Dopam | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Do | 2001 |
Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Chemistry; Cerebral Cortex; Chromatography, Hi | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Behavior, Animal; Body Weight; Corpus Striat | 2002 |
Oxidative stress and dopamine deficiency in a genetic mouse model of Lesch-Nyhan disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aconitate Hydratase; Animals; Cell Death; Disease Models, Animal; Do | 2002 |
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Behavior, Animal; Cell Count; Cell Death; | 2002 |
Behavioral consequences of methamphetamine-induced neurotoxicity in mice: relevance to the psychopathology of methamphetamine addiction.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine-Related Disorders; Animals; Behavior, Animal; Binding Si | 2002 |
Adaptation to repeated cocaine administration in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Cocaine; Cocaine-Related Disorders; Cortic | 2002 |
Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acute Disease; Animals; Chronic Disease; Dialysis; Disease Models, A | 1992 |
CNS monoamines and their metabolites in canine narcolepsy: a replication study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dogs; Dopamine; Hydroxyindol | 1990 |
Biogenic amines distribution in the brain of nervous and normal pointer dogs. A genetic animal model of anxiety.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anxiety; Biogenic Amines; Brain Chemistry; Disease Models, | 1990 |
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1991 |
Neuropeptide changes in a primate model (Cebus apella) for tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Cebus; Corpus Striatum; | 1990 |
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; | 1990 |
[Effect of monoamine neurotransmitters in the hypothalamus in a cortisol-induced rat model of yang-deficiency].
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Disease Models, Animal; Dopamine; Epin | 1990 |
Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; DNA; Dopamine; Enz | 1990 |
Catecholaminergic responses to rotational stress in rat brain stem: implications for amphetamine therapy of motion sickness.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Brain Stem; Disease Models, Animal; Homovanill | 1990 |
Contents of monoamines in forebrain regions of alcohol-preferring (P) and -nonpreferring (NP) lines of rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Alcoholism; Animals; Biogenic Amines; Brain; Cereb | 1987 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid | 1985 |
Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Model | 1985 |
Plasma catecholamines and urinary excretion of their main metabolites in three models of portal hypertension.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamines; Disease Models, Animal; Dopamine; Homovanil | 1988 |
Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 1986 |
The use of the MPTP-treated mouse as an animal model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1987 |